These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 29736709)
21. Aberrant signal transduction pathways in myeloproliferative neoplasms. Kota J; Caceres N; Constantinescu SN Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448 [TBL] [Abstract][Full Text] [Related]
22. Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform. Tang H; Duggan S; Richardson PL; Marin V; Warder SE; McLoughlin SM J Biomol Screen; 2016 Feb; 21(2):201-11. PubMed ID: 26676096 [TBL] [Abstract][Full Text] [Related]
23. [Gene mutations in myeloproliferative neoplasms]. Araki M; Morishita S; Komatsu N Rinsho Ketsueki; 2016; 57(12):2526-2534. PubMed ID: 28090022 [TBL] [Abstract][Full Text] [Related]
24. Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective. Yang BB; Doshi S; Arkam K; Franklin J; Chow AT Clin Pharmacokinet; 2016 Sep; 55(9):1045-58. PubMed ID: 27056734 [TBL] [Abstract][Full Text] [Related]
25. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546 [TBL] [Abstract][Full Text] [Related]
27. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery. Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529 [TBL] [Abstract][Full Text] [Related]
28. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Tefferi A Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973 [TBL] [Abstract][Full Text] [Related]
29. Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening. Duellman SJ; Zhou W; Meisenheimer P; Vidugiris G; Cali JJ; Gautam P; Wennerberg K; Vidugiriene J Assay Drug Dev Technol; 2015 Oct; 13(8):456-65. PubMed ID: 26383544 [TBL] [Abstract][Full Text] [Related]
31. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284 [TBL] [Abstract][Full Text] [Related]
32. Using Thermogenic Beige Cells to Identify Biologically Active Small Molecules and Peptides. Wu L; Xu B Methods Mol Biol; 2017; 1566():203-212. PubMed ID: 28244053 [TBL] [Abstract][Full Text] [Related]
35. High-Throughput Screen of GluK1 Receptor Identifies Selective Inhibitors with a Variety of Kinetic Profiles Using Fluorescence and Electrophysiology Assays. Solly K; Klein R; Rudd M; Holloway MK; Johnson EN; Henze D; Finley MF J Biomol Screen; 2015 Jul; 20(6):708-19. PubMed ID: 25700884 [TBL] [Abstract][Full Text] [Related]
36. JAK and MPL mutations in myeloid malignancies. Tefferi A Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515 [TBL] [Abstract][Full Text] [Related]
37. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α. Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700 [TBL] [Abstract][Full Text] [Related]
38. Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists. Reiter LA; Jones CS; Brissette WH; McCurdy SP; Abramov YA; Bordner J; DiCapua FM; Munchhof MJ; Rescek DM; Samardjiev IJ; Withka JM Bioorg Med Chem Lett; 2008 May; 18(9):3000-6. PubMed ID: 18396041 [TBL] [Abstract][Full Text] [Related]
39. Phenotype-driven chemical screening in zebrafish for compounds that inhibit collective cell migration identifies multiple pathways potentially involved in metastatic invasion. Gallardo VE; Varshney GK; Lee M; Bupp S; Xu L; Shinn P; Crawford NP; Inglese J; Burgess SM Dis Model Mech; 2015 Jun; 8(6):565-76. PubMed ID: 25810455 [TBL] [Abstract][Full Text] [Related]
40. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Rampal R; Levine RL Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]